Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines

被引:7
作者
Mitsiades, CS
Sykoutri, D
McMullan, C
Poulaki, V
Mitsiades, N
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Angiogenesis Lab, Boston, MA 02114 USA
关键词
D O I
10.1210/jc.2003-030968
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:5043 / 5044
页数:2
相关论文
共 7 条
  • [1] Bcr-Abl inhibition as a modality of CML therapeutics
    Buchdunger, E
    Matter, A
    Druker, BJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01): : M11 - M18
  • [2] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    Druker, BJ
    Tamura, S
    Buchdunger, E
    Ohno, S
    Segal, GM
    Fanning, S
    Zimmermann, J
    Lydon, NB
    [J]. NATURE MEDICINE, 1996, 2 (05) : 561 - 566
  • [3] Druker BJ, 2002, J NATL CANCER I, V94, P1660
  • [4] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Druker, BJ
    Talpaz, M
    Resta, DJ
    Peng, B
    Buchdunger, E
    Ford, JM
    Lydon, NB
    Kantarjian, H
    Capdeville, R
    Ohno-Jones, S
    Sawyers, CL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
  • [5] Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL(+) leukemic cells and induces apoptosis
    GambacortiPasserini, C
    leCoutre, P
    Mologni, L
    Fanelli, M
    Bertazzoli, C
    Marchesi, E
    DiNicola, M
    Biondi, A
    Corneo, GM
    Belotti, D
    Pogliani, E
    Lydon, NB
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 1997, 23 (19) : 380 - 394
  • [6] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    Kantarjian, H
    Sawyers, C
    Hochhaus, A
    Guilhot, F
    Schiffer, C
    Gambacorti-Passerini, C
    Niederwieser, D
    Resta, D
    Capdeville, R
    Zoellner, U
    Talpaz, M
    Druker, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) : 645 - 652
  • [7] The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
    Podtcheko, A
    Ohtsuru, A
    Tsuda, S
    Namba, H
    Saenko, V
    Nakashima, M
    Mitsutake, N
    Kanda, S
    Kurebayashi, J
    Yamashita, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) : 1889 - 1896